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Open access under In vitro genotoxicity assays are often used to compare tobacco smoke particulate matter (PM) from dif-
ferent cigarettes. The quantitative aspect of the comparisons requires appropriate statistical methods and
replication levels, to support the interpretation in terms of power and signiﬁcance. This paper recom-
mends a uniform statistical analysis for the Ames test, mouse lymphoma mammalian cell mutation assay
(MLA) and the in vitro micronucleus test (IVMNT); involving a hierarchical decision process with respect
to slope, ﬁxed effect and single dose comparisons. With these methods, replication levels of 5 (Ames test
TA98), 4 (Ames test TA100), 10 (Ames test TA1537), 6 (MLA) and 4 (IVMNT) resolved a 30% difference in
PM genotoxicity.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
In vitro tests for genotoxicity are an important part of regulatory
toxicology in many sectors, e.g. food and pharmaceuticals, espe-
cially in the detection of potential carcinogens (Combes et al.,
2007; DOH, 2000; ICH, 1997; Kirkland et al., 2003; Pfuhler et al.,
2007). The Ames test, mouse lymphoma mammalian cell mutation
assay (MLA) and in vitro micronucleus test (IVMNT) are among the
most effective methods. The Ames test measures bacterial mutage-
nicity, the MLA measures mammalian mutagenicity and the
IVMNT measures structural and numerical chromosome changes.
IVMNT has been validated for the detection of genotoxic carcino-
gens (Anon, 2006; Corvi et al., 2008; Matsushima et al., 1999).ORESTA, Cooperation Centre
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CC BY-NC-ND license. Ames test, MLA and IVMNT methods have been recommended by
the Organisation for Economic Cooperation and Development
(OECD), the International Conference on Harmonisation of Techni-
cal Requirements for Registration of Pharmaceuticals for Human
Use (ICH) or the United Kingdom Environmental Mutagenesis
Society (UKEMS). (Gatehouse et al., 1990; ICH, 1995, 1997; OECD,
1997a,b, 2010; UKEMS, 1989). The methods include statistical
analysis and replication levels to aid the qualitative interpretation
of the results.
Tobacco smoke contains gas and particulate phases. The latter
can be trapped on glass ﬁbre ﬁlters, and extracted as particulate
matter (PM). PM is used for in vitro tests, because its preparation
is well deﬁned, it gives clear dose responses and there is a large
amount of historic control data. PM is genotoxic in the Ames test,
MLA and IVMNT (Baker et al., 2004; Clive et al., 1997; Cobb et al.,
1989; DeMarini, 2004; Kier et al., 1974; Mitchell et al., 1981;
Richter et al., 2010; Rickert et al., 2007, 2011; Roemer et al.,
2002, 2004; Sato et al., 1977). The Cooperation Centre for Scientiﬁc
Research Relative to Tobacco (CORESTA) has recommended
descriptive statistics, to characterise PM dose responses in the
Ames test and IVMNT (CORESTA, 2004, 2010).
The in vitro methods have also been able to quantitatively dif-
ferentiate PMs from a variety of cigarettes (DeMarini et al., 2008;
Guo et al., 2011; Roemer et al., 1998). Novel tobacco materials
can reduce PM genotoxicity (Combes et al., 2012; McAdam et al.,
2011). Quantitative comparison of PMs’ genotoxicity could support
the development of Reduced Toxicant Prototype tobacco products,
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work (Proctor and Ward, 2011).
The aim of this paper is to recommend statistical methods and
replication levels for the quantitative comparison of test and con-
trol PMs in the Ames test, IVMNT and MLA.2. Materials and methods
2.1. Test materials
3R4F cigarettes were obtained from the University of Kentucky.
These are ﬁltered American blend reference cigarettes, with a PM
yield of approximately 11 mg/cigarette under International Stan-
dards Organisation (ISO) machine smoking conditions (Roemer
et al., 2012).
PM preparation was as described by McAdam et al. (2011).
Brieﬂy, cigarettes were conditioned according to ISO 3402 (ISO,
1999), then smoked on a RM20CSR smoking machine (Borgwalt-
KC, Hamburg, Germany) according to ISO 3308 (ISO, 2000). An
appropriate number of cigarettes were smoked to obtain up to
300 mg PM on a 44 mm Cambridge ﬁlter pad. PM was eluted in
dimethyl sulphoxide (DMSO) to a concentration of 24 mg/ml.
Samples were shipped at 80 C to an independent laboratory
for in vitro tests, where they were stored at80 C in single-use ali-
quots, and used within 1 month.
To conﬁrm the in vitro assays’ resolving power, two 3R4F PMs
were tested. These were from the same PM stock solution, but
one sample was diluted to 70% (v/v), to simulate a 30% difference
between PMs.
2.2. In vitro toxicology testing
All in vitro tests were performed in an independent Good Labo-
ratory Practice laboratory. Post-mitochondrial supernatant (S9),
prepared from male Sprague Dawley rats, induced with Aroclor
1254, was used for metabolic activation.
The Ames test was performed as described by McAdam et al.
(2011), with the exceptions that only three Salmonella typhimurium
strains were used (TA98, TA100 and TA1537), in the presence of S9,
and there were 8 replicate plates per dose. Results are presented as
mean revertants/lg PM ± standard error of the mean (SEM), within
each experiment.
The MLA was performed as described by McAdam et al. (2011),
with the exception six replicate cultures per dose were exposed to
PM for 24 h without S9. Data are plotted as the means of replicate
cultures ± SEM, within each experiment.
The IVMNT was performed as described by McAdam et al.
(2011), with the exception that six replicate V79 cell cultures per
dose were pulsed with test samples for 3 h followed by a 21 h
recovery, without S9. Data are plotted as the means of replicate
cultures ± SEM, within each experiment.
The exceptions to McAdam et al. (2011) represent the selection
of the most sensitive treatment conditions and an increase in rep-
lication levels, to evaluate the statistical methods. The replication
levels were selected following a review of historical data, indicat-
ing the scope to increase resolving power.
2.3. Statistical analysis
Different outlier, transformation and linearity methods were
evaluated using recent PM data, as follows.
Dixon’s test (Böhrer, 2008) and boxplot quartiles (Tukey, 1977)
were used to identify potential outliers.
The assumed distributions for the Ames test, MLA and IVMNT
were Poisson (Roller and Aufderheide, 2008), log-normal (Murphyet al., 1988) and binomial (Hayashi et al., 1994), respectively. A
generalised linear model was used, to accommodate response
variables that have other than a normal distribution. This required
logarithmic transformations for the Ames test and MLA, and a pro-
bit transformation for the IVMNT (Armitage and Berry, 1987a).
Two ways to identify the linear part of the dose response
(Bernstein et al., 1982) were evaluated. The ﬁrst was to use a linear
regression model and partition the residual error into pure error
and lack-of-ﬁt (Draper and Smith, 1998). The linear portion of
the response was identiﬁed by systematically excluding doses
from the model until the lack-of-ﬁt test was non-signiﬁcant. The
second method ﬁtted a generalised linear model with linear and
quadratic terms for dose (Roller and Aufderheide, 2008). If the qua-
dratic term was signiﬁcant (p < 0.01), the same model was ﬁtted
again with the highest dose excluded, continuing until the qua-
dratic term was not signiﬁcant or less than three doses remained.
Dose responses were compared and signiﬁcance tested using
analysis of covariance (ANCOVA) for slopes and pooled data, and
t-tests for individual concentrations (Werley et al., 2008).
Following ANCOVA (Pocock et al., 2002) or t-tests, resolving
power was calculated using standard formulae (Armitage and
Berry, 1987b).3. Results
3.1. Evaluation of statistical methods
3.1.1. Identiﬁcation of potential outliers
Dixon’s test occasionally identiﬁed single values as potential
outliers, when the other replicate values were close together. The
quartiles method required more than 6 replicates per dose. Fur-
thermore, removing potential outliers did not improve the resolv-
ing power of the assays, except for TA1537 data in the Ames test.
With sufﬁcient replication (>6 replicates per dose), the quartiles
method was used to improve the resolving power of TA1537 data,
by identifying potential outliers for removal, before further statis-
tical analysis. Outlier analysis was not applied in the other assays.
3.1.2. Transformations
Examination of the residuals conﬁrmed that the number of
revertants in an Ames test were Poisson distributed (Roller and
Aufderheide, 2008), the proportion of micronucleated binucleate
cells (MnBn) in the IVMNT were binomially distributed and muta-
tion frequency (MF) in the MLA was normally distributed on the
log scale, consistent with the assumed distributions of these trans-
formation methods.
3.1.3. Linearity
Identiﬁcation of linearity through partitioning residual errors
from simple linear regression was shown to be unreliable, because
the errors were not always normally distributed. Fitting a general-
ised linear model with linear and quadratic terms for dose, and
removing the highest dose until the quadratic term was not signif-
icant, also identiﬁed the linear part of the dose response, and the
residuals were consistent with the method’s assumptions.
3.1.4. Signiﬁcance tests
The linear portion of the curve was used to compare the slopes
of dose responses. A test for difference in slopes was investigated
using an analysis of covariance model containing terms for dose,
PM and a PM-by-dose interaction term. Where PM-by-dose was
signiﬁcant (p < 0.05), the difference in slopes was statistically
signiﬁcant. Occasionally, linear dose responses were parallel
(PM-by-dose pP 0.05). The PM samples were then compared for
differences in overall magnitudes (mean responses). This was done
Fig. 1. Statistical methods to compare PM genotoxicity in the Ames test, MLA and IVMNT.
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covariate and a term for PM as a ﬁxed effect. Where the PM term
was signiﬁcant (p < 0.05), the difference in magnitudes was statis-
tically signiﬁcant.
There were also some data-sets where a linear part of the dose
response could not be established for one or both of the PM sam-
ples. In this case, different PMs were compared at each common
dose level using t-tests, two-sided at the 5% level of signiﬁcance.
For the MLA, Levene’s test (Levene, 1960) for equality of vari-
ances between the two PM samples was performed prior to the
t-test and where this showed evidence of heterogeneity (p < 0.01)
the data was rank transformed prior to analysis (Conover andTable 1
Estimation of replication levels to resolve different PMs in genotoxicity assays.
Assaya Parameter
Ames testc TA98 Slope
Pooled
Dose
TA100 Slope
Pooled
Dose
TA1537d Slope
Pooled
Dose
MLAe Slope
Pooled
Dose
IVMNTf Slope
Pooled
Dose
a Data generated using the replication levels given in Section 2.
b 80% Power, p < 0.05, two-tailed, compared to 3R4F PM.
c With S9.
d Outliers removed.
e 24 h Treatment without S9.
f 3 h Treatment without S9.Iman, 1981). Levene’s test is used to test if samples have equal vari-
ances. Equal variances across samples is called homogeneity of var-
iance. Some statistical tests, for example the t-test, assume that
variances are equal across groups or samples. Levene’s test can
be used to verify that assumption.
For the Ames test and IVMNT, the data was Poisson and binomi-
ally distributed respectively, thus standard parametric tests based
on the assumption of normally distributed data are not appropriate
and the data were rank transformed prior to the t-test. Rank trans-
formation procedures are ones in which the usual parametric ap-
proach is applied to the ranks of the data instead of the data
themselves. In situations where the number of observations isReplicate cultures Resolvable difference (%)b
1–10 10.8–11.9
5 30
5 30
1–10 17.8–19.6
3 30
4 30
1–10 23.8–26.2
10 30
8 30
1–10 23.8–26.2
6 30
6 30
2–10 28.2–29.9
3 30
3 30
Fig. 2. Bacterial mutagenicity of PM in Salmonella typhimurium strain TA98 with S9 metabolic activation. Points plotted are the means of 5 replicate cultures ± SEM.
_______j_______ 3R4F PM, - - - -d- - - - 70% (v/v) 3R4F PM.
Fig. 3. Bacterial mutagenicity of PM in Salmonella typhimurium strain TA100 with S9 metabolic activation. Points plotted are the means of 4 replicate cultures ± SEM.
_______j_______ 3R4F PM, - - - -d- - - - 70% (v/v) 3R4F PM.
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it is not possible to obtain statistically signiﬁcant differences at all.
Therefore for these assays the analysis of rank transformed data is
considered to be more appropriate.
The combined statistical methods are summarised in Fig. 1.
3.2. Estimation of replication levels
Historical data was reviewed to identify the most responsive
PM treatment conditions for each assay. The most sensitive re-
sponses in the Ames test were obtained with TA98, TA100 and
TA1537, and S9 metabolic activation. In MLA and IVMNT the most
sensitive responses were obtained with 24 h and 3 h PM exposures
without S9, respectively. These treatments were selected for power
calculations.
The genotoxicity of two different 3R4F PMs were measured in
each assay. Power calculations were performed on the slopes of
the dose responses, pooled data and each concentration separately,to estimate the number of replicates per concentration that would
detect a 30% increase or decrease in the response, with 80% power,
at p < 0.05. The results are summarised in Table 1.
The levels of replication typically used in these assays (e.g. 3 in
the Ames test, 4 in MLA and 2 in IVMNT), could resolve a 30% dif-
ference in PM genotoxicity, in terms of slope. Replication levels of 5
(Ames test TA98), 4 (Ames test TA 100), 10 (Ames test TA1537), 6
(MLA) and 3 (IVMNT) would be required for similar resolution, in
terms of pooled data or individual doses.
3.3. Conﬁrmation of replication levels
Two 3R4F PMs were tested, to conﬁrm the resolving power of
these replication levels. These were from the same PM stock solu-
tion, but one sample was diluted to 70% (v/v), to simulate a 30%
difference between PMs. The two PM samples were compared in
each assay. Replication levels were as described in Table 1 for com-
parisons at common doses, except for IVMNT where 4 replicate
Fig. 4. Bacterial mutagenicity of PM in Salmonella typhimurium strain TA1537 with S9 metabolic activation. Points plotted are the means of 10 replicate cultures ± SEM.
_______j_______ 3R4F PM, - - - -d- - - - 70% (v/v) 3R4F PM.
Fig. 5. Mammalian cell mutation frequency in LY5178Y tk ± cells exposed to PM for 24 h without S9 metabolic activation. Points plotted are the means of 6 replicate
cultures ± SEM. _______j_______ 3R4F PM, - - - -d- - - - 70% (v/v) 3R4F PM.
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have been powerful enough to detect differences if we had to
revert to t-tests at each common dose level. The results are
shown in Figs. 2–6. Linearity was identiﬁed in all dose responses
(Tables 2a and 2b). Differences between the PM samples were
statistically signiﬁcant in all three assays. This conﬁrmed that
replication levels of 5 (Ames test TA98), 4 (Ames test TA 100), 10
(Ames test TA1537), 6 (MLA) and 4 (IVMNT) can resolve 30%
differences in PM genotoxicity.
The resolving power was based on estimates of intra-experiment
variability. It is consistent with the differences in PM genotoxicity
observed by others (Combes et al., 2012; McAdam et al., 2011;
Oldham et al., 2012; Roemer et al., 1998).4. Discussion
3R4F was genotoxic in the Ames test, MLA and IVMNT. This is
consistent with published observations (Baker et al., 2004; Cliveet al., 1997; Cobb et al., 1989; DeMarini, 2004; DeMarini et al.,
2008; Guo et al., 2011; Kier et al., 1974; McAdam et al., 2011;
Mitchell et al., 1981; Richter et al., 2010; Rickert et al., 2007,
2011; Roemer et al., 2002, 2004; Sato et al., 1977).
Guidelines for testing genotoxicity with the Ames test, MLA and
IVMNT (ICH, 1995; OECD, 1997a,b, 2010) emphasize the assays’
biological responses rather than giving advice on appropriate
statistical techniques. The OECD states that ‘‘biological relevance
of the results should be considered ﬁrst. Statistical methods may
be used as an aid in evaluating test results. Statistical signiﬁcance
should not be the only determining factor for a positive response’’
(OECD, 1997a). This approach has led to some heterogeneity in sta-
tistical techniques for analysing genotoxicity using data from these
assays. Non-linear methods (Myers et al., 1981), t-tests (Clapp
et al., 1999) and factorial analysis (Rickert et al., 2007) are some
of the techniques that have been implemented for analysing data
from these assays.
Statistical techniques related to the Ames test are well docu-
mented. Ames data are commonly accepted to follow a Poisson
Fig. 6. Micronucleus induction in V79 cells exposed to PM for 3 h without S9 metabolic activation. Points plotted are the means of 4 replicate cultures ± SEM. _______j_______
3R4F PM, - - - -d- - - - 70% (v/v) 3R4F PM.
Table 2a
Conﬁrmation of the resolving power of the Ames test and MLA for different PMs.
Assay Slope of the dose responsea
3R4F PM 70% (v/v) 3R4F PM
Ames test TA98 1.353 0.891*
TA100 0.357 0.285*
TA1537 0.088 0.059*,b
MLA 0.0258 0.0182*
* Signiﬁcantly lower than 3R4F PM, p < 0.01 (Ames test), p < 0.05 (MLA).
a Revertants/lg PM (Ames test), log MF/lg PM (MLA).
b Outliers excluded.
Table 2b
Conﬁrmation of the resolving power of IVMNT for different PMs.
Assay Mean responsea
3R4F PM 70% (v/v) 3R4F PM
IVMNT 0.0374 0.0300*
* Signiﬁcantly lower than 3R4F PM, p < 0.01.
a Proportion of MnBn cells/lg PM.
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advised to assess the assumption of equal conditional mean and
variance (Kirkland, 1994). There is also a tendency to analyse
responses by comparing the slope of the linear portion of the curve
(Bernstein et al., 1982; Kirkland, 1994; Roemer et al., 2002, 2004,
2012; Roller and Aufderheide, 2008).
There is less information published concerning statistical
methods for analysing MLA and IVMNT data. Non-linear
techniques have been employed (Irr and Snee, 1982; Roemer
et al., 2012), as have trend tests (Murphy et al., 1988) or Markov
Chain Monte Carlo (MCMC) approaches (Guo et al., 2011). There
is no predominant statistical approach for analysing MLA data even
though the natural logarithm of the mutant frequencies has been
accepted to be approximately normally distributed (Irr and Snee,
1982; Murphy et al., 1988). Similarly, IVMNT data is accepted to
follow a binomial distribution (Hayashi et al., 1994).
How useful these statistical approaches are, is largely deter-
mined by their ability for detecting differences between different
test agents. This ability is characterised as the statistical power
which is directly related to the number of replicates used in the
analysis. For quantitative comparisons of different PMs, there islittle information about the number of replicates that should be
performed for each type of assay. Three replicates per concentra-
tion have been used in the Ames test (Gaworski et al., 2008;
Stavanja et al., 2006) and IVMNT (Carmines et al., 2005). Four repli-
cates per concentration have been used in the MLA (Guo et al., 2011).
This paper provides a common statistical approach for the com-
parison of different PMs, in the Ames test, MLA and IVMNT (Fig. 1).
Dose responses were compared as slopes, intercepts or at common
doses, depending on the linearity of the responses. The linear part
of the dose response was identiﬁed statistically, using adaptions to
accommodate the log-normal and binomial distributions of MLA
and IVMNT data respectively. This approach has simpliﬁed the
implementation of statistical comparisons of different PMs in these
genotoxicity tests. Quantitative differences were detected.
With these statistical methods, replication levels were charac-
terised in terms of resolving power. Replication levels of 5 (Ames
test TA98), 4 (Ames test TA 100), 10 (Ames test TA1537), 6 (MLA)
and 4 (IVMNT) resolved 30% differences and could accommodate
occasional non-linear responses. In the MLA, six replicate cultures
per dose might restrict experimental design by exceeding the max-
imum number of cultures in one study. In this case, reducing the
replication level to four cultures per dose would have a negligible
effect on resolving power (30–40%).
Data from individual experiments could be combined into one
larger analysis. However, care should be taken with this approach.
The methods discussed here were powered and designed to ﬁnd
differences within an experiment, not across several experiments.
By combining experiments, small differences that are not scientif-
ically relevant, might acquire statistical signiﬁcance.
This statistical approach was developed to compare PMs, but
could also be applied to comparing other products’ in vitro
genotoxicities. It could add conﬁdence to any differences observed
and limit apparent similarities to the resolving power of the assay.
While in vitro tests alone cannot measure human risk, they can
contribute to a Weight of Evidence paradigm for the risk assess-
ment of Reduced Toxicant Prototype (RTP) tobacco products.
Together with smoke composition, in vitro disease models, appro-
priate in vivo data, bio-markers of exposure and of biological effect,
and smoking behaviour data, in vitro genotoxicity studies can help
to test the hypothesis that the biological signiﬁcance of exposure
to tobacco and/or tobacco smoke toxicants from RTP tobacco prod-
ucts has been reduced, without introducing new genotoxic
hazards.
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